Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [extended cohort]

ABSTRACT: A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [extended cohort]

PROVIDER: PRJNA671693 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12890300.fastq.gz	Fastqsanger.gz
	SRR12890400.fastq.gz	Fastqsanger.gz
	SRR12890500.fastq.gz	Fastqsanger.gz
	SRR12890600.fastq.gz	Fastqsanger.gz
	SRR12890700.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 1702

Similar Datasets

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [extended cohort]

Project description:Population scale sweeps of viral pathogens, such as SARS-CoV-2, require high intensity testing for effective management. However, reliable systems affording parallel testing of thousands of patients for pathogen infection have not yet been routinely employed. Here we describe “Systematic Parallel Analysis of RNA coupled to Sequencing for Covid-19 screening” (C19-SPAR-Seq), a multiplexed, readily automated platform for SARS-CoV-2 detection capable of analyzing tens of thousands of patient samples in a single instrument run. To address strict requirements for control of assay parameters and output demanded by clinical diagnostics, we employed a control-based Precision-Recall and Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of several hundred patients performed with a specificity of 100% and sensitivity of 91% on samples with low viral loads. Our study thus establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.

2021-01-24 | GSE160034 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [pilot cohort]

2021-01-24 | GSE160033 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [test cohort]

2021-01-24 | GSE160032 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [PoC cohort]

2021-01-24 | GSE160031 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [PoC cohort]

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [PoC cohort]

| PRJNA671680 | ENA

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [test cohort]

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [test cohort]

| PRJNA671682 | ENA

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [pilot cohort]

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [pilot cohort]

| PRJNA671689 | ENA

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

| PRJNA671674 | ENA

High-throughput Microwell-seq 2.0 reveals massively multiplexed chemical perturbation

Project description:Combining in-cell RT and Microwell-seq 1.0, we established Microwell-seq 2.0 for cost-effective HTS with scRNA-seq-based phenotyping. To assess the fidelity of the Microwell-seq 2.0, we performed a species-mixing experiment with cultured human (293T) and mouse (3T3) cells. Moreover, we assessed the platform on tissue cells with more heterogeneous cell types. By harnessing the power of Microwell-seq 2.0, we analyzed massively multiplexed chemical perturbation of human embryonic stem cells (hESCs) at the single-cell resolution.

2021-11-09 | GSE175413 | GEO

A multiplexed, next generation sequencing platform for high-throughput detection of SARS-CoV-2.

Project description:Population scale sweeps of viral pathogens, such as SARS-CoV-2, require high intensity testing for effective management. Here, we describe "Systematic Parallel Analysis of RNA coupled to Sequencing for Covid-19 screening" (C19-SPAR-Seq), a multiplexed, scalable, readily automated platform for SARS-CoV-2 detection that is capable of analyzing tens of thousands of patient samples in a single run. To address strict requirements for control of assay parameters and output demanded by clinical diagnostics, we employ a control-based Precision-Recall and Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of several hundred patients performs with a specificity of 100% and sensitivity of 91% on samples with low viral loads, and a sensitivity of >95% on high viral loads associated with disease onset and peak transmissibility. This study establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.

| S-EPMC7930244 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data